There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cytokinetics (CYTK – Research Report) and Blueprint Medicines (BPMC – Research Report) with bullish sentiments.
Cytokinetics (CYTK)
In a report released yesterday, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Cytokinetics, with a price target of $122.00. The company’s shares closed last Tuesday at $81.19.
According to TipRanks.com, Mamtani has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Cytokinetics is a Strong Buy with an average price target of $89.13, representing an 8.0% upside. In a report issued on January 2, J.P. Morgan also maintained a Buy rating on the stock with a $78.00 price target.
See the top stocks recommended by analysts >>
Blueprint Medicines (BPMC)
JMP Securities analyst Reni Benjamin reiterated a Buy rating on Blueprint Medicines yesterday and set a price target of $114.00. The company’s shares closed last Tuesday at $80.52.
According to TipRanks.com, Benjamin has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Blueprint Medicines with a $86.06 average price target, a 5.6% upside from current levels. In a report issued on January 2, Guggenheim also maintained a Buy rating on the stock with a $90.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CYTK:
- Cytokinetics extends decline, down 26% after WSJ said Novartis back away
- Novartis backing away from pursuit of Cytokinetics, WSJ reports
- Cytokinetics sinks 23% after WSJ says Novartis backed away from takeover
- Notable open interest changes for January 10th
- M & A News: CYTK Stock Drops, Novartis Deal Hopes Diminish
